



Technology Advisory Committee A Interests Register Andexanet alfa for reversing anticoagulation [ID1101]

Publication Date: 12/05/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TAC Committee Member	Non-financial professional & personal interest	Member of the relevant Evidence Review Group for this appraisal	NA	04/03/2020	NA	It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Dr Deepa Jayakody Arachchillage	Clinical expert	Indirect interest	Gave an expert lecture in a meeting supported by Portola Pharmaceuticals. There was no direct contact with Portola Pharmaceuticals as the invitation to the lecture came from PCM scientific.	NA	24/12/2019	NA	It was agreed that this declaration would not prevent Dr Arachchillage from providing expert advice to the committee.
Mr Diederik Bulters	Clinical expert	Direct financial interest	Received a consultancy fee in 2016 for providing expert opinion and feedback to Portola Pharmaceuticals on Andexanet alfa.	NA	01/02/2021	NA	It was agreed that this declaration would not prevent Mr Bulters from providing expert advice to the committee.



Professor Elizabeth Warburton	prof	Non-financial professional & personal interest	Local PI on various RCTs: Ongoing Tenecteplase (thrombolysis) trials: ATTEST – Trial Steering group committee and local PI. Have stepped down from both roles for committee.	NA	17/01/2020	NA	It was agreed that these declarations would not prevent Professor Warburton from providing expert advice to the committee
			TASTE and TWIST trials stepped down from local PI role. UK Thrombectomy trial.				
			STABILISE – local PI (trial now finished and published) CHARM (cerebral oedema) - stepped down as local PI.				
			 Head positioning after stroke trial HEADPOST – local PI (trial now finished and published). 				
			 Blood pressure after stroke trials INTERACT – Local PI (trial finished and published). 				
			 ENCHANTED - local PI (no longer recruiting) 				
			Participated in the OPTIMAS trial; a British Heart Foundation and Stroke Association funded multicentre trial on the timing of the start of anticoagulants in				



			patients with AF following ischemic stroke. Awarded the Pfizer Pharmaceuticals Grant for innovation in stroke prevention in AF after national competition via the NHS Academic Health Sciences Networks (£250,000 awarded Dec 2016)				
Professor Elizabeth Warburton	Clinical expert	Non-financial professional & personal interest	Topic advisor for the NICE CG Stroke Rehabilitation guidelines committee Board member of the NIHR HTA Clinical Trials Advisory Panel (since 2020) Honorary Treasurer British Association of Stroke	NA	27/01/2021	NA	It was agreed that these declarations would not prevent Professor Elizabeth Warburton from providing expert advice to the committee.
			Physicians (2020-) Editorial board of the AHA journal Stroke (from 2020).				
Mr Patrick Grover	Clinical Expert	Direct financial interest	Participated in two Delphi consensuses for Portola Pharmaceuticals regarding this drug, for which he was received renumeration.	NA	31/01/2021	NA	It was agreed that this declaration would not prevent Mr Grover from providing expert advice to the committee.